Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Ovarian Neoplasms 3Neoplasms 3Glioblastoma 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Solid Tumors 1Solid Tumor 1Small Cell Lung Carcinoma 1Sarcoma 1Neuroectodermal Tumors 1Nervous System Diseases 1Neoplasms by Site 1Neoplasms by Histologic Type 1Head and Neck Neoplasms 1HER2-negative Breast Cancer 1Gliosarcoma 1For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment 1Esophageal Neoplasms 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1Advanced Malignant Solid Neoplasm 1Advanced Malignancies 1

Interventions

adavosertib 2veliparib 1trametinib 1pamiparib 1cabozantinib 1Temozolomide 1Everolimus 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Malignant Solid Neoplasm × pamiparib × Clear all
NCT05038839 2026-05-12

Cabozantinib and Pamiparib for the Treatment of Advanced of Refractory Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Completed
44 enrolled
Other solid neoplasm

Advanced Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡